The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
 
Milton Jose De Barros E Silva
No Relationships to Disclose
 
Monique Celeste Tavares
No Relationships to Disclose
 
Joao Paulo S. N. Lima
No Relationships to Disclose
 
Daniel Garcia
No Relationships to Disclose
 
Jose Augusto Rinck Jr
No Relationships to Disclose
 
Andre Molina
No Relationships to Disclose
 
Matheus Lobo
No Relationships to Disclose
 
Clovis Antonio Lopes Pinto
No Relationships to Disclose
 
Rafaela Brito De Paula
No Relationships to Disclose
 
Alexander Christopher Jonathan van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
João Pedreira Duprat Neto
No Relationships to Disclose